- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04480229
Telenursing and Breast Cancer: The Turkish Case
A Randomized Controlled Study on the Influence of Telenursing Services to the Chemotherapy Treatment of Breast Cancer Patients: The Turkish Case
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- is volunteering to participate in the research,
- is 18 years of age or over,
- can communicate in Turkish,
- has Turkish literacy skills,
- has no hearing, vision problems, and mental disability that may hinder communication,
- is female,
- has a diagnosis of breast cancer for the first time in her life and consequently receiving chemotherapy treatment in the same protocols for the first time,
- did not have a different diagnosis of cancer and related chemotherapy treatment.
Exclusion Criteria:
- Having been diagnosed with breast cancer before and received chemotherapy treatment accordingly,
- Having been diagnosed with different cancers before and had chemotherapy treatment related to it,
- Cancer treatment with oral medications,
- Refuse to participate in the study
- Refuse education/counseling
- Not knowing Turkish
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Intervention Group
After the first treatment, every week the patients were called and consulted by telenursing.
During the next there chemotherapy treatments, Edmonton Symptom Assessment System and General Comfort Questionnaire were filled.
The study ended with the fourth cycle chemotherapy.
A total of six telephone calls and 3 face-to-face follow-ups were done with each of the intervention group patients.
Face-to-face follow-up with patients during chemotherapy treatments lasted for about 20-30 minutes, and patients were evaluated three times in terms of symptom severity and comfort level.
|
After the first face-to-face training, counseling on the phone was conducted every week for four cycles of chemotherapy treatment.
In total, six counseling sessions and four face-to-face training sessions were conducted for each patient.
|
|
NO_INTERVENTION: No Intervention: Control Group
During their first treatment the "Patient Identification Form" was filled and they were trained, which is the routine practice of the clinic.
Patients were informed about the "Symptom follow-up form", asked to mark the symptoms and signs they experienced due to the disease and treatment in the form between the two chemotherapy treatments and to note when they experienced and how they resolved this symptom.
When the patients came to the second treatment, the first follow-up of the patients was done.
The investigator filled Edmonton Symptom Assessment System and General Comfort Questionnaire forms via face-to-face interviews.
The "Symptom Follow-up Form" given to the patients in the previous chemotherapy treatment was collected and the same new form was given.
They were requested to bring this form in their next treatment.
The same protocol was followed during the third and fourth chemotherapy treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Edmonton Symptom Assessment System
Time Frame: 10 minutes
|
This tool is designed to assist in the assessment of symptoms common in cancer patients: pain,fatique, nausea, sadness, anxiety, insomnia, anorexia, wellbeing and shortness of breath, change in skin-nails, mucositis and numbness in hands.
The patient circles the most appropriate number to indicate where the symptom is between "0" and "10".
"0" is the minimum value, which means there is no change and it is a better outcome for the patient.
"10" is the maximum value, means that the symptom level is the highest, which is a worse outcome for the patient.
|
10 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
General Comfort Questionnaire
Time Frame: 10 minutes
|
It is used to evaluate the situation of achieving the expected comfort increase result with nursing interventions that provide comfort. The scale, which is a four-point likert type, has a total of 48 items, 24 items are positive and 24 items are negative. The lowest value that can be taken is 1 which indicates low comfort and this is a worse outcome. The highest value 4 indicates high comfort, which is a better outcome. The response patterns of the scale, which consists of positive and negative items, are given in mixed form. Accordingly, from positive statements; high score (4p) indicates high comfort, low score (1p) indicates low comfort, while negative items indicate low comfort (1p), high score (4p) low comfort. |
10 minutes
|
Collaborators and Investigators
Investigators
- Principal Investigator: Cicek Yagci, Ph.D., Istinye University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 50687469-1280-2190-14
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Female
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
Dalarna County Council, SwedenRecruitingBreast Cancer - FemaleSweden
-
Al-Quds UniversityNot yet recruitingThe Effect of Psychosocial Support on Improving Breast Cancer Patients Response to Medical TreatmentBreast Cancer - FemalePalestinian Territories
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of Kansas Medical CenterRecruitingBreast Cancer FemaleUnited States
-
Izmir Biomedicine and Genome CenterDokuz Eylul University; Antalya Training and Research Hospital; Akdeniz University...Enrolling by invitationFemale Breast Cancer PatientsTurkey (Türkiye)
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
-
Carebot s.r.o.CompletedBreast Neoplasms | Breast Cancer Screening | Breast Cancer Detection | Breast Cancer - FemaleCzechia, Slovakia
-
Dana-Farber Cancer InstituteBreast Cancer Research FoundationNot yet recruitingBreast Cancer | Breast Carcinoma | ER Positive Breast Cancer | Breast Cancer - Female | PR-Positive Breast CancerUnited States
-
Sarah Sammons, MDStemline Therapeutics, Inc.RecruitingBreast Cancer | Metastatic Breast Cancer | Breast Cancer Female | HER2-negative Breast Cancer | HER2 Low Breast CarcinomaUnited States
Clinical Trials on Telenursing and Counseling
-
Dursun Alper YILMAZCompletedHypertension | Telenursing | NursingTurkey
-
Vanderbilt University Medical CenterTerminatedIdiopathic Pulmonary FibrosisUnited States
-
Zahide AksoyThe Scientific and Technological Research Council of TurkeyCompletedCopd | Self Efficacy | Empowerment | Empowerment, PatientTurkey
-
Suleyman Demirel UniversityRecruiting
-
University of Applied Sciences of Western SwitzerlandSwiss National Science Foundation; University of Lausanne Hospitals; Réseau d... and other collaboratorsCompletedInflammatory RheumatismSwitzerland
-
Ondokuz Mayıs UniversityCompletedTelemedicine | TelenursingTurkey
-
Hasan Kalyoncu UniversityCompleted
-
Fernanda Maria Alves LimaFaculdade de Medicina de Botucatu, UNESP, Botucatu, BrasilNot yet recruiting
-
Çankırı Karatekin UniversityCompletedPain | Fibromyalgia Syndrome | Tele-nursingTurkey (Türkiye)
-
Federal University of BahiaFundação de Amparo à Pesquisa do Estado da BahiaUnknown